Ocera Therapeutics

Ocera’s lead drug candidate OCR-002 is a novel ammonia scavenger which rapidly removes ammonia from the blood. Elevated ammonia is believed to be one of the primary causes of hepatic encephalopathy (HE). OCR-002 is the subject of STOP-HE, a Company-sponsored Phase 2b trial, and two investigator-sponsored Phase 2a trials. OCR-002 has received Orphan Drug designation in both the U.S. and Europe and has been granted Fast Track status by the U.S. Food and Drug Administration.

Company Growth (employees)
Type
Public
HQ
Palo Alto, US
Founded
2005
Size (employees)
19 (est)-5%
Ocera Therapeutics was founded in 2005 and is headquartered in Palo Alto, US

Ocera Therapeutics Office Locations

Ocera Therapeutics has offices in Palo Alto and Durham
Palo Alto, US (HQ)
610 525 University Ave
Durham, US
300 5001 S Miami Blvd

Ocera Therapeutics Data and Metrics

Ocera Therapeutics Financial Metrics

Ocera Therapeutics's revenue was reported to be $35 k in Q3, 2015
USD

Net income (Q1, 2017)

(6.7 m)

Market capitalization (15-Aug-2017)

27.7 m

Cash (31-Mar-2017)

25.2 m
Ocera Therapeutics's current market capitalization is $27.7 m.
USDFY, 2016

R&D expense

16.1 m

General and administrative expense

10.4 m

Operating expense total

26.5 m

Net Income

(26.9 m)
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Revenue

33 k233 k31 k43 k35 k

R&D expense

4.8 m4.2 m4.4 m3.4 m4.2 m4.7 m3.9 m4.3 m3.9 m

General and administrative expense

2.4 m2.7 m2.3 m2.8 m2.4 m2.6 m3 m2.6 m2.5 m

Operating expense total

7.2 m6.9 m6.7 m6.2 m6.6 m7.3 m6.9 m6.9 m6.4 m

Net Income

(11.3 m)(17.9 m)(6.7 m)(12.9 m)(19.4 m)(7.5 m)(7.1 m)(7.1 m)(6.7 m)
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.5 m10.1 m35.9 m24.6 m

Accounts Receivable

93 k62 k59 k

Inventories

470 k970 k627 k584 k

Current Assets

49.3 m48.3 m44 m28.9 m

PP&E

59 k61 k94 k64 k

Goodwill

595 k595 k595 k595 k

Total Assets

51.8 m53.1 m44.7 m29.6 m

Accounts Payable

1.3 m941 k701 k1.2 m

Total Debt

19 m

Current Liabilities

6.7 m2.9 m3.8 m13.8 m

Total Liabilities

13.9 m

Additional Paid-in Capital

126.6 m155.1 m162.8 m174.1 m

Retained Earnings

(104.9 m)(131.4 m)(158.3 m)

Total Equity

31.4 m15.7 m

Debt to Equity Ratio

0.6 x

Debt to Assets Ratio

0.4 x

Financial Leverage

1.4 x1.9 x
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Cash

12.5 m8.3 m10.3 m8.4 m22.8 m32.4 m34.2 m29.2 m25.2 m

Accounts Receivable

33 k32 k31 k74 k35 k93 k

Current Assets

44.5 m42 m48.6 m40.5 m35.9 m33.2 m25.9 m

PP&E

75 k69 k53 k45 k109 k82 k69 k63 k54 k

Goodwill

595 k595 k595 k595 k595 k595 k595 k595 k595 k

Total Assets

39.8 m57.7 m47.5 m42.7 m49.4 m41.2 m36.6 m33.9 m26.6 m

Accounts Payable

1.3 m1.1 m1 m1.1 m1 m1.3 m1.4 m2.1 m1.2 m

Current Liabilities

3.3 m3 m3.5 m5 m6 m7.3 m13.1 m

Additional Paid-in Capital

129.3 m154.1 m156 m157.4 m160.7 m165.7 m168 m172 m178.5 m

Retained Earnings

(92.8 m)(99.4 m)(111.6 m)(117.8 m)(124.4 m)(138.9 m)(146.1 m)(153.2 m)(165 m)

Total Equity

36.5 m54.7 m44.5 m39.6 m36.4 m26.7 m21.9 m18.8 m13.5 m

Financial Leverage

1.1 x1.1 x1.1 x1.1 x1.4 x1.5 x1.7 x1.8 x2 x
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(17.5 m)(23.4 m)(26.5 m)(26.9 m)

Depreciation and Amortization

295 k164 k171 k

Accounts Receivable

45 k31 k3 k

Accounts Payable

14 k(341 k)(240 k)514 k

Cash From Operating Activities

(12 m)(20.3 m)(20.6 m)(22.1 m)

Purchases of PP&E

(12 k)(38 k)(75 k)(14 k)

Cash From Investing Activities

(21.3 m)(8.9 m)33.2 m3.6 m

Cash From Financing Activities

7.2 m

Interest Paid

828 k
USDQ2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017

Net Income

(11.3 m)(17.9 m)(6.7 m)(12.9 m)(19.4 m)(7.5 m)(7.1 m)(7.1 m)(6.7 m)

Depreciation and Amortization

102 k151 k49 k98 k146 k12 k

Accounts Receivable

60 k61 k31 k(12 k)27 k(34 k)

Accounts Payable

11 k(239 k)88 k134 k73 k544 k1.4 m2.1 m1.2 m

Cash From Operating Activities

(10.4 m)(16.1 m)(4.9 m)(10.1 m)(15.1 m)(5.2 m)

Purchases of PP&E

(23 k)(38 k)(71 k)

Cash From Investing Activities

7 m(14.9 m)5.1 m8 m15.5 m(21 k)

Cash From Financing Activities

1.8 m

Interest Paid

207 k
Y, 2017

Financial Leverage

2 x

Ocera Therapeutics Market Value History

Traffic Overview of Ocera Therapeutics

Ocera Therapeutics Online and Social Media Presence

Ocera Therapeutics Company Life and Culture

You may also be interested in